Dr. Carles Celma

- Scientific Director at Kymos
- Active in Drug research and development for over 30 years
- Extensive experience in Mass Spectrometry
- Expert in biologics and biosimilars
- Wide experience in method development, validation and sample analysis using physicochemical, binding and cellular methods for regulated analysis
Experience
While working on his PhD at University, Carles Celma was responsible of the Mass Spectrometry Facility at the Chemistry Faculty.
He then started to work for Ipsen as Head of Mass Spectrometry in 1990 and left in 2012 as the Director of Bioanalysis. That year, Celma joined Kymos as Biologics Scientific Director.
Expertise
Dr. Carles Celma has more than 40 communications to congresses and 10 publications in different international journals (see list of publications). In addition, he publishes regularly on Kymos’ webpage.
Education
Celma graduated 1981 from the University of Barcelona with a degree in Organic Chemistry and acquired 1990 a PhD in Organic Chemistry.
Want to get to know him better?
Read about him on researchgate.
List of publications:
- Celma and E. Giralt, “Optimization of the Experimental Procedures in Fast Atom Bombardment Mass Spectrometry of Peptides with a Quadrupole Mass Spectrometer”, Biomed. Mass Spectrom., 1990, 19, 235‑239.
- Celma and E. Giralt, “Determination of the Enantiomeric Purity of Synthetic Peptides by Gas Chromatography‑Mass Spectrometry”, J. Chromatogr. Biomed. Applications, 1991, 562, 447‑458.
- “Convergent Solid Phase Peptide Synthesis IX: Application to the Synthesis of Peptides with Repetitive Sequences”, C. Celma, F. Albericio, E. Pedroso and E. Giralt., Peptide Research, 5, 62‑70, (1992).
- Celma, “Determination of the aza alkyl lysophospholipid 3-methoxy 2-N,N-methyloctadecyl amino propyloxy-phosphoryl choline in rat plasma by liquid chromatography particle beam mass spectrometry”, J. Chromatogr. Biomed. Applications, 1993, 622, 215-222.
- Celma, “Determination of the Platelet activating factor antagonist 6-(2-chlorophenyl)-9-[(4-methoxy phenyl)thio carbamoyl]-1- methyl-7,8,9,10-tetra hydro-4H-pyrido [4′,3′- 4,5] – Thieno [3,2-f][1,2,4,]triazolo [4,3-a][1,4] diazepine in human plasma by liquid chromatography – thermospray mass spectrometry”, J. Chromatography B, 1994, 657, 214-218.
- Celma, “Mass Spectrometry and Liquid Chromatography / Mass Spectrometry of Some Derivates of 6-(2-chlorophenyl)-1-methyl-7,8,9,10-tetra hydro-4H-pyrido [4′,3′- 4,5] – Thieno [3,2-f][1,2,4,]triazolo [4,3-a][1,4] diazepines”. Biological Mass Spectrometry, 1994, 23, 13-19.
- Celma, J.A. Allué, J. Pruñonosa, C. Peraire, R. Obach, “Determination of N-Acetylcysteine in human plasma by liquid chromatography coupled to tandem mass spectrometry”, J. Chromatography A, 2000, 870, 13-22.
- Celma, J.A. Allué, J. Pruñonosa, C. Peraire, R. Obach. “Simultaneous determination of paracetamol and chlorpheniramine in human plasma by liquid chromatography – tandem mass spectrometry”. J. Chromatography A, 2000, 870, 77-86.
- Ventura, J. Solà, C. Celma, C. Peraire and R. Obach, “In Vitro Metabolism of Irosustat, A Novel Steroid Sulphatase Inhibitor: Inter-Species Comparison, Metabolite Identification and Metabolic Enzyme Identification”, Drug Metabolism and Disposition, 2011, 39, 1235-1246.
- Morte C, Celma C, De Geyter C, Urbancsek J, Coroleu Lletget B, Cometti B. Assessment of the immunogenicity of gonadotrophins during controlled ovarian stimulation. Am J Reprod Immunol. 2017 Sep;78(3).
Neutralizing Antibodies: Testing, Guidelines and Impact for Biologics
Biologics and Advanced Therapies Medicinal Products (ATMPs) are revolutionizing the future of medicine, and their safety and efficacy are two top priorities. A key aspect of this process is the immune response they may [...]
Dissolution Testing: What it is, How we do it, and Why it matters
Dissolution testing is a fundamental analytical technique in the pharmaceutical industry, providing information on how a drug is released from its dosage form. This analysis is vital for ensuring product quality, predicting performance in [...]
Endotoxin Testing: A Complete Approach at Kymos Group
At Kymos Group, we continuously expand our analytical capabilities to support and match the needs of the pharmaceutical and biotech industries with state-of-the-art quality control solutions. Endotoxin testing is crucial when dealing with the [...]
Denosumab Biosimilars: Accelerating Drug Development for RANKL Inhibitors
Denosumab represents one of the leading biologics applied today in various diseases of bones: treatment and prevention of osteoporosis, bone metastases, and other skeletal disorders. Its success in improving patient health has made it [...]
New FDA Guideline for Oligonucleotide Therapeutics
In June 2024, the FDA published the final version of the guideline titled “Clinical Pharmacology Considerations for the Development of Oligonucleotide Therapeutics Guidance for Industry”. This document replaces the draft from 2022 and provides [...]
New EMA Guideline on Topical Products: Impact on IVRT and IVPT
The European Medicines Agency (EMA) announced in October 2024 the adoption of the long-awaited guideline on the Quality and Equivalence of Topical Products. The final document was drafted back in 2018 and will be coming [...]
Events
Join us at our upcoming events
Farmaforum: Madrid, ES | 17–18 Sep 2025
Bioproduction Congress (BIOPC): Lyon, FR | 22 – 23 Sep 2025
KoNECT-MOHW-MFDS International Conference: Seoul, KR | 22 – 24 Sep 2025
Festival of Biologics: Basel, CH | 30 Sep – 02 Oct 2025
BIOSPAIN: Barcelona, ES | 07-09 Oct 2025
ESGCT Congress: Sevilla, ES | 07-10 Oct 2025
BIOPLUS INTERPHEX KOREA: Seoul, KR | 15-17 Oct 2025
OTS Anual Meeting: Budapest, HU | 19-22 Oct 2025
CPHI 2025: Frankfurt, DE | 28-30 Oct 2025
I4ID MabDesign: Lyon, FR | 13-14 Nov 2025
European Bioanalysis Forum (EBF): Barcelona, ES | 18-20 Nov 2025
PharmaLab Congress: Düsseldorf, DE | 24-26 Nov 2025
BioFIT: Strasbourg, FR | 02-03 Dec 2025
Get in touch with us